NCT06687629

Brief Summary

Concha bullosa (CB) refers to the condition where the middle turbinate's interior is aerated (making the turbinate wide and thick). CB can narrow the middle meatus and the ostiomeatal complex. In adults suffering from chronic sinusitis, the prevalence of CB is approximately 34%. The most common treatment method for CB is turbinate crushing. This is considered a conservative treatment that preserves the mucous membranes relatively intact without opening the interior of the turbinate. Another fairly common method is the removal of the lateral part of the bullous middle turbinate. Opening the CB and removing the lateral part of the middle turbinate can lead to adhesions between the middle turbinate and the lateral wall of the nose. These adhesions can impede airflow and narrow or completely close the ostium or the surgically created middle meatal antrostomy. Crushing the CB is technically easier and possibly a less traumatic procedure. However, it is suspected that some of these crushed bullous turbinates may refill. The development of a mucocele is another potential issue. Crushing might be a better option compared to resection in the long term. Preserving the mucous membranes during crushing may reduce the formation of adhesions, which are sometimes seen after resection of the middle turbinate. The purpose of the study is to investigate the long-term benefits and side effects of CB treatment methods. The study will include 60 patients undergoing a basic Functional Endoscopic Sinus Surgery (FESS) procedure due to recurrent or chronic maxillary sinusitis. The patients will be randomized, with 31 undergoing resection and 31 undergoing crushing. Before the procedure, patients will undergo a CT scan (NSO-TT) and symptom evaluation through various questionnaires. All patients will also undergo nasoscopy. One year after the procedure, the patients' conditions will be reassessed (questionnaires, nasoscopy, NSO-TT only if necessary), including the need for revision surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 21, 2018

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 12, 2023

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

November 12, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 13, 2024

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

March 10, 2026

Status Verified

October 1, 2024

Enrollment Period

5.3 years

First QC Date

November 12, 2024

Last Update Submit

March 7, 2026

Conditions

Keywords

concha bullosasinusitisconcha bullosa resectionconcha bullosa crushingchronic sinusitissinusitis bacterial

Outcome Measures

Primary Outcomes (1)

  • postoperative SNOT-22

    postoperative SNOT-22 score

    1 year

Secondary Outcomes (1)

  • LM endoscopy score

    1 year

Other Outcomes (1)

  • Antibiotics usage postoperatively

    1 year

Study Arms (2)

crushing

ACTIVE COMPARATOR

Concha bullosa crushing group

Procedure: Concha bullosa crushing

resection

ACTIVE COMPARATOR

Concha bullosa resection group

Procedure: Concha bullosa resection

Interventions

Concha bullosa crushing

crushing

Concha bullosa resection

resection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • chronic or recurrent rhinosinusitis
  • months of regular nasal corticosteroid usage
  • No prior endoscopic procedures of the paranasal sinuses
  • EPOS criteria for CRS are met: inflammation of the paranasal sinuses with at least 2 symptoms, one of which must be nasal obstruction/congestion or nasal discharge (anterior/posterior):
  • facial pain/pressure in the facial area
  • reduced or lost sense of smell SNOT-22 25 or higher
  • Complications of CRS (e.g., mucocele)
  • Pregnancy/breastfeeding or plans for them in the near future
  • Coagulation disorders
  • Systemic diseases: cystic fibrosis, primary ciliary dysfunction, sarcoidosis, Wegener's granulomatosis
  • Immunosuppression: diagnosed SAD, CVI, HIV, or use of biological/immunosuppressive drugs
  • Immunotherapy
  • Daily use of systemic corticosteroids
  • Communication issues (non-Finnish-speaking patient, neurological/psychiatric problems)
  • SNOT-22 score \< 25

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Helsinki University Hospital Ear Clinic

Helsinki, Uusimaa, 00130, Finland

Location

Related Publications (1)

  • Dogru H, Uygur K, Tuz M. Concha bullosa squeezer for turbinoplasty (Dogru forceps). J Otolaryngol. 2004 Apr;33(2):111-3. doi: 10.2310/7070.2004.02112. No abstract available.

    PMID: 15518100BACKGROUND

MeSH Terms

Conditions

Sinusitis

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsParanasal Sinus DiseasesNose DiseasesRespiratory Tract DiseasesOtorhinolaryngologic Diseases

Study Officials

  • Markus Lilja, PhD

    Helsinki University Central Hospital

    STUDY DIRECTOR
  • Mario Järvekülg, MD

    Helsinki University Central Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
specialist doctor

Study Record Dates

First Submitted

November 12, 2024

First Posted

November 13, 2024

Study Start

March 21, 2018

Primary Completion

July 12, 2023

Study Completion

December 31, 2025

Last Updated

March 10, 2026

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

According to the data protection regulations, patients' personal data cannot be shared publicly in Finland.

Locations